Combined IL6 and CCR2 blockade potentiates antitumor activity of NK cells in HPV-negative head and neck cancer

Abstract Background While T cell-activating immunotherapies against recurrent head and neck squamous cell carcinoma (HNSCC) have shown impressive results in clinical trials, they are often ineffective in the majority of patients. NK cells are potential targets for immunotherapeutic intervention; how...

Full description

Bibliographic Details
Main Authors: Fan Yang, Chenyang Yuan, Fanghui Chen, Zhaohui S. Qin, Nicole C. Schmitt, Gregory B. Lesinski, Nabil F. Saba, Yong Teng
Format: Article
Language:English
Published: BMC 2024-03-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Online Access:https://doi.org/10.1186/s13046-024-03002-1
_version_ 1797258932558757888
author Fan Yang
Chenyang Yuan
Fanghui Chen
Zhaohui S. Qin
Nicole C. Schmitt
Gregory B. Lesinski
Nabil F. Saba
Yong Teng
author_facet Fan Yang
Chenyang Yuan
Fanghui Chen
Zhaohui S. Qin
Nicole C. Schmitt
Gregory B. Lesinski
Nabil F. Saba
Yong Teng
author_sort Fan Yang
collection DOAJ
description Abstract Background While T cell-activating immunotherapies against recurrent head and neck squamous cell carcinoma (HNSCC) have shown impressive results in clinical trials, they are often ineffective in the majority of patients. NK cells are potential targets for immunotherapeutic intervention; however, the setback in monalizumab-based therapy in HNSCC highlights the need for an alternative treatment to enhance their antitumor activity. Methods Single-cell RNA sequencing (scRNA-seq) and TCGA HNSCC datasets were used to identify key molecular alterations in NK cells. Representative HPV-positive ( +) and HPV-negative ( −) HNSCC cell lines and orthotopic mouse models were used to validate the bioinformatic findings. Changes in immune cells were examined by flow cytometry and immunofluorescence. Results Through integration of scRNA-seq data with TCGA data, we found that the impact of IL6/IL6R and CCL2/CCR2 signaling pathways on evasion of immune attack by NK cells is more pronounced in the HPV − HNSCC cohort compared to the HPV + HNSCC cohort. In orthotopic mouse models, blocking IL6 with a neutralizing antibody suppressed HPV − but not HPV + tumors, which was accompanied by increased tumor infiltration and proliferation of CD161+ NK cells. Notably, combining the CCR2 chemokine receptor antagonist RS504393 with IL6 blockade resulted in a more pronounced antitumor effect that was associated with more activated intratumoral NK cells in HPV − HNSCC compared to either agent alone. Conclusions These findings demonstrate that dual blockade of IL6 and CCR2 pathways effectively enhances the antitumor activity of NK cells in HPV-negative HNSCC, providing a novel strategy for treating this type of cancer.
first_indexed 2024-04-24T23:01:23Z
format Article
id doaj.art-48f5164039c74ea981c7b089b4993884
institution Directory Open Access Journal
issn 1756-9966
language English
last_indexed 2024-04-24T23:01:23Z
publishDate 2024-03-01
publisher BMC
record_format Article
series Journal of Experimental & Clinical Cancer Research
spelling doaj.art-48f5164039c74ea981c7b089b49938842024-03-17T12:42:10ZengBMCJournal of Experimental & Clinical Cancer Research1756-99662024-03-0143111710.1186/s13046-024-03002-1Combined IL6 and CCR2 blockade potentiates antitumor activity of NK cells in HPV-negative head and neck cancerFan Yang0Chenyang Yuan1Fanghui Chen2Zhaohui S. Qin3Nicole C. Schmitt4Gregory B. Lesinski5Nabil F. Saba6Yong Teng7Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory UniversityDepartment of Biostatistics and Bioinformatics, Rolling School of Public Health, Emory UniversityDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory UniversityDepartment of Biostatistics and Bioinformatics, Rolling School of Public Health, Emory UniversityDepartment of Otolaryngology, Emory UniversityDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory UniversityDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory UniversityDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory UniversityAbstract Background While T cell-activating immunotherapies against recurrent head and neck squamous cell carcinoma (HNSCC) have shown impressive results in clinical trials, they are often ineffective in the majority of patients. NK cells are potential targets for immunotherapeutic intervention; however, the setback in monalizumab-based therapy in HNSCC highlights the need for an alternative treatment to enhance their antitumor activity. Methods Single-cell RNA sequencing (scRNA-seq) and TCGA HNSCC datasets were used to identify key molecular alterations in NK cells. Representative HPV-positive ( +) and HPV-negative ( −) HNSCC cell lines and orthotopic mouse models were used to validate the bioinformatic findings. Changes in immune cells were examined by flow cytometry and immunofluorescence. Results Through integration of scRNA-seq data with TCGA data, we found that the impact of IL6/IL6R and CCL2/CCR2 signaling pathways on evasion of immune attack by NK cells is more pronounced in the HPV − HNSCC cohort compared to the HPV + HNSCC cohort. In orthotopic mouse models, blocking IL6 with a neutralizing antibody suppressed HPV − but not HPV + tumors, which was accompanied by increased tumor infiltration and proliferation of CD161+ NK cells. Notably, combining the CCR2 chemokine receptor antagonist RS504393 with IL6 blockade resulted in a more pronounced antitumor effect that was associated with more activated intratumoral NK cells in HPV − HNSCC compared to either agent alone. Conclusions These findings demonstrate that dual blockade of IL6 and CCR2 pathways effectively enhances the antitumor activity of NK cells in HPV-negative HNSCC, providing a novel strategy for treating this type of cancer.https://doi.org/10.1186/s13046-024-03002-1Head and neck cancerNK cellsIL6 and CCR2scRNA-seqHPVThe tumor microenvironment
spellingShingle Fan Yang
Chenyang Yuan
Fanghui Chen
Zhaohui S. Qin
Nicole C. Schmitt
Gregory B. Lesinski
Nabil F. Saba
Yong Teng
Combined IL6 and CCR2 blockade potentiates antitumor activity of NK cells in HPV-negative head and neck cancer
Journal of Experimental & Clinical Cancer Research
Head and neck cancer
NK cells
IL6 and CCR2
scRNA-seq
HPV
The tumor microenvironment
title Combined IL6 and CCR2 blockade potentiates antitumor activity of NK cells in HPV-negative head and neck cancer
title_full Combined IL6 and CCR2 blockade potentiates antitumor activity of NK cells in HPV-negative head and neck cancer
title_fullStr Combined IL6 and CCR2 blockade potentiates antitumor activity of NK cells in HPV-negative head and neck cancer
title_full_unstemmed Combined IL6 and CCR2 blockade potentiates antitumor activity of NK cells in HPV-negative head and neck cancer
title_short Combined IL6 and CCR2 blockade potentiates antitumor activity of NK cells in HPV-negative head and neck cancer
title_sort combined il6 and ccr2 blockade potentiates antitumor activity of nk cells in hpv negative head and neck cancer
topic Head and neck cancer
NK cells
IL6 and CCR2
scRNA-seq
HPV
The tumor microenvironment
url https://doi.org/10.1186/s13046-024-03002-1
work_keys_str_mv AT fanyang combinedil6andccr2blockadepotentiatesantitumoractivityofnkcellsinhpvnegativeheadandneckcancer
AT chenyangyuan combinedil6andccr2blockadepotentiatesantitumoractivityofnkcellsinhpvnegativeheadandneckcancer
AT fanghuichen combinedil6andccr2blockadepotentiatesantitumoractivityofnkcellsinhpvnegativeheadandneckcancer
AT zhaohuisqin combinedil6andccr2blockadepotentiatesantitumoractivityofnkcellsinhpvnegativeheadandneckcancer
AT nicolecschmitt combinedil6andccr2blockadepotentiatesantitumoractivityofnkcellsinhpvnegativeheadandneckcancer
AT gregoryblesinski combinedil6andccr2blockadepotentiatesantitumoractivityofnkcellsinhpvnegativeheadandneckcancer
AT nabilfsaba combinedil6andccr2blockadepotentiatesantitumoractivityofnkcellsinhpvnegativeheadandneckcancer
AT yongteng combinedil6andccr2blockadepotentiatesantitumoractivityofnkcellsinhpvnegativeheadandneckcancer